Core Laboratories Amends Q4 2025 Earnings, Corrects Tax Expense by $4.2M

summarizeSummary

Core Laboratories amended its Q4 2025 earnings report, correcting an understatement of income tax expense by $4.2 million, which reduced diluted EPS by $0.09, but did not impact revenue or operating income.

check_boxKey Events

• Corrected Q4 2025 Financials

  The company understated income tax expense for the quarter and year ended December 31, 2025, by $4.2 million. This correction decreased net income by $4.2 million and diluted earnings per share by $0.09 for both periods.

• Prior Period Adjustments

  Additional adjustments were made to the consolidated balance sheet as of December 31, 2024, including a $4.7 million misclassification and a $5.6 million write-off of unrecoverable income taxes receivable from prior to 2021, impacting beginning retained earnings.

• No Operational Impact

  The company emphasized that these adjustments did not affect consolidated revenue, operating income, income before tax, or cash from operations, indicating that the core business performance is not impacted.

auto_awesomeAnalysis

Core Laboratories Inc. filed an amendment to its February 4, 2026 8-K to correct previously reported financial results for the fourth quarter and full year 2025. The company understated income tax expense by $4.2 million, which consequently reduced net income by the same amount and diluted earnings per share by $0.09. This correction is material as it revises reported profitability. However, the company clarified that this adjustment did not impact consolidated revenue, operating income, income before tax, or cash from operations, suggesting the core operational performance remains unchanged. Investors should note the revised EPS figures and the impact on retained earnings from prior period adjustments, while recognizing that the underlying business performance is not affected by these accounting corrections.